For
31° European Congress of Pathology

Nice, 8 September 2019
Progress is future and young people are our future. Also in scientific research field. I want to support researchers in order to help patients to survive.

Umberto Veronesi

Scientific research allows knowledge progress

Research converts knowledge into concrete benefits
OUR GOALS

Fondazione Veronesi promotes scientific progress focusing on two main fields of action:

**SCIENTIFIC RESEARCH**
- Research grants
- Research projects
- European School of Molecular Medicine (SEMM) in Milan

**SCIENTIFIC DISSEMINATION**
- Conferences and meetings
- School projects and laboratories
- Publications
- Web magazine www.fondazioneveronesi.it
Since 2003, Fondazione Veronesi has increasingly supported high-level research in oncology, cardiology, neuroscience and healthy lifestyle.

The research areas are identified by our scientific committee, composed by 39 multidisciplinary experts from 26 national and foreign institutes.

Every year Fondazione Veronesi funds research grants through a public call dedicated to Italian and foreign institutes.
Selection criterias aim to support excellent researchers working on ground-breaking projects with a high translational potential.
OUR NUMBERS FROM 2003 TO 2019

1576 Researchers

116 International research projects

8 Pediatric oncology treatment protocols

3 Observational studies
Breast cancer is the most common type of cancer that affects women, with **1,000 new cases every day** in Europe.

**Every year in Italy 52,300 women** get sick. Thanks to research, if breast cancer is detected early, almost **90% survive the disease**. An estimated **94,378 new cases** of breast cancer are diagnosed in **sub-Saharan Africa annually**

The average age at diagnosis in sub-Saharan Africa (35–49 years) is **lower** than in high-income countries, which is due to the high proportion of young people in these countries. Incidence rates vary greatly worldwide from 19.3 per 100,000 women in Eastern Africa to 89.7 per 100,000 women in Western Europe.

**Breast cancer survival rates vary greatly worldwide**, ranging from 80% or over in North America, Sweden and Japan to around 60% in middle-income countries and below 40% in low-income countries (Coleman et al., 2008).

The low survival rates in less developed countries can be explained mainly by the lack of early detection programmes, resulting in a high proportion of women presenting with late-stage disease, as well as by the lack of adequate diagnosis and treatment facilities.

Pink is Good is Fondazione Veronesi’s projects to finance excellent research against female cancers and to promote prevention in Italy and abroad.

* GLOBOCAN database:
Breast cancer survival rates vary greatly worldwide, ranging from 80% or over in North America, Sweden and Japan to around 60% in middle-income countries and below 40% in low-income countries (Coleman et al., 2008).

The low survival rates in less developed countries can be explained mainly by the lack of early detection programmes, resulting in a high proportion of women presenting with late-stage disease, as well as by the lack of adequate diagnosis and treatment facilities.
The 24 March 2013, Fondazione Umberto Veronesi opened a Center for the free diagnosis of breast cancer at the Maternity Hospital in Herat (38,000 visits per year) with the support of Rezai Foundation, the Italian Embassy in Kabul and the Italian Cooperation in Afghanistan
The Case History of Herat (Afghanistan)
The Case History of Herat (Afghanistan)

The Center today
The Afghan Doctor Farzana Rasaouli (a gynecologist), Head of the Center, was trained twice in Milan (2012 and in 2015), in India (2017) and in Perugia (2018) in radiology screening techniques thanks to the support of APOF (Association of Pathologists beyond Borders) and in partnership with the General Hospital Santa Maria della Misericordia of Perugia and USL1 of Umbria.
Simultaneously, in Perugia, a training in cytology of three months for an afghan Doctor and a Biologist was held (February – April 2018).
After the trainings in Italy, an internal laboratory of Cytology, fully equipped, was set-up in June 2018 at the Center of Herat.
Thanks to the agreement between Fondazione Umberto Veronesi and APOF (Association of Pathologists beyond Borders), in the person of Dr. Daniela Fenocchio, a **tele-pathology system has been set-up** to perform quality checks in remotely reading slides for the first few years at least.
The Case History of Herat –
The team

Currently, the staff of the Center is composed by:

- **2 Doctors**: Farzana Rasaouli and Fatema Fareshta
- **1 Biologist**: Fareshta Fizli
- **2 Radiology Technicians**: Sadaf Qayumi and Sadiqa Farooqi
- **1 Data-manager**: Sumaia Banai
The Case History of Herat – Every day activity

In 2018, over 1,070 women were visited for free in the Center. Since 2013, over 8,000 patients have been welcomed.
The Case History of Herat – Relevant Data

Number of needle aspirates to date 436

Percentage of suspicious / malignant lesions (categories C4-C5) 9%

Concordance between proposed diagnoses and our revision > 90%
**BREAST CANCER PREVENTION UNIT IN HERAT – Cytology Report**

From January up to September 2019

<table>
<thead>
<tr>
<th></th>
<th>January</th>
<th>February</th>
<th>March</th>
<th>April</th>
<th>May</th>
<th>June</th>
<th>July</th>
<th>August</th>
<th>Up to 5th sep</th>
<th>Total</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>2%</td>
</tr>
<tr>
<td>C2</td>
<td>11</td>
<td>8</td>
<td>12</td>
<td>7</td>
<td>15</td>
<td>11</td>
<td>9</td>
<td>13</td>
<td>1</td>
<td>87</td>
<td>39%</td>
</tr>
<tr>
<td>C3</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>16</td>
<td>7%</td>
</tr>
<tr>
<td>C4</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>0</td>
<td>18</td>
<td>8%</td>
</tr>
<tr>
<td>C5</td>
<td>7</td>
<td>5</td>
<td>5</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>7</td>
<td>4</td>
<td>40</td>
<td>18%</td>
</tr>
<tr>
<td>Abscess</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>24</td>
<td>11%</td>
</tr>
<tr>
<td>Glactocele</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>2%</td>
</tr>
<tr>
<td>Cyst</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>6</td>
<td>4</td>
<td>5</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>28</td>
<td>13%</td>
</tr>
<tr>
<td><strong>Total Client</strong></td>
<td>26</td>
<td>24</td>
<td>23</td>
<td>27</td>
<td>33</td>
<td>28</td>
<td>18</td>
<td>34</td>
<td>8</td>
<td>221</td>
<td>100%</td>
</tr>
</tbody>
</table>
## BREAST CANCER PREVENTION AREA IN HERAT – Mammography Report

From January up to September 2019

<table>
<thead>
<tr>
<th></th>
<th>January</th>
<th>February</th>
<th>March</th>
<th>April</th>
<th>May</th>
<th>June</th>
<th>July</th>
<th>August</th>
<th>Up to 5th sep</th>
<th>Total</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Mammogram</td>
<td>88</td>
<td>86</td>
<td>36</td>
<td>85</td>
<td>55</td>
<td>55</td>
<td>102</td>
<td>42</td>
<td>7</td>
<td>556</td>
<td>63%</td>
</tr>
<tr>
<td>Axillary Lymph Node</td>
<td>37</td>
<td>27</td>
<td>23</td>
<td>30</td>
<td>15</td>
<td>14</td>
<td>36</td>
<td>26</td>
<td>4</td>
<td>212</td>
<td>24%</td>
</tr>
<tr>
<td>Benign Lesion</td>
<td>5</td>
<td>3</td>
<td>2</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>4</td>
<td>0</td>
<td>44</td>
<td>5%</td>
</tr>
<tr>
<td>Suspected Breast Cancer</td>
<td>14</td>
<td>6</td>
<td>1</td>
<td>6</td>
<td>3</td>
<td>3</td>
<td>9</td>
<td>5</td>
<td>3</td>
<td>50</td>
<td>6%</td>
</tr>
<tr>
<td>Nodule</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>9</td>
<td>1%</td>
</tr>
<tr>
<td>Vascular Calcification</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>10</td>
<td>1%</td>
</tr>
<tr>
<td><strong>Total Client</strong></td>
<td>149</td>
<td>126</td>
<td>63</td>
<td>133</td>
<td>80</td>
<td>80</td>
<td>158</td>
<td>78</td>
<td>14</td>
<td>881</td>
<td>100%</td>
</tr>
</tbody>
</table>
### BREAST CANCER PREVENTION AREA IN HERAT – Sonography Report

From January up to September 2019

<table>
<thead>
<tr>
<th></th>
<th>January</th>
<th>February</th>
<th>March</th>
<th>April</th>
<th>May</th>
<th>June</th>
<th>July</th>
<th>August</th>
<th>Up to 5th Sep</th>
<th>Total</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Sonography</td>
<td>96</td>
<td>84</td>
<td>112</td>
<td>94</td>
<td>82</td>
<td>54</td>
<td>16</td>
<td>2</td>
<td>2</td>
<td>542</td>
<td>66%</td>
</tr>
<tr>
<td>Suspected Breast Cancer</td>
<td>8</td>
<td>9</td>
<td>6</td>
<td>4</td>
<td>6</td>
<td>5</td>
<td>7</td>
<td>6</td>
<td>0</td>
<td>51</td>
<td>6%</td>
</tr>
<tr>
<td>Complex mass</td>
<td>3</td>
<td>7</td>
<td>5</td>
<td>7</td>
<td>8</td>
<td>4</td>
<td>2</td>
<td>5</td>
<td>2</td>
<td>43</td>
<td>5%</td>
</tr>
<tr>
<td>Axillary lymph node</td>
<td>1</td>
<td>5</td>
<td>6</td>
<td>9</td>
<td>5</td>
<td>4</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>32</td>
<td>4%</td>
</tr>
<tr>
<td>Hypo echoic mass</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6</td>
<td>1%</td>
</tr>
<tr>
<td>Abscess</td>
<td>3</td>
<td>1</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>17</td>
<td>2%</td>
</tr>
<tr>
<td>Nodule</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0.24%</td>
</tr>
<tr>
<td>Cyst</td>
<td>6</td>
<td>4</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>4</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>31</td>
<td>4%</td>
</tr>
<tr>
<td>Solid Mass</td>
<td>14</td>
<td>6</td>
<td>11</td>
<td>10</td>
<td>21</td>
<td>15</td>
<td>6</td>
<td>13</td>
<td>5</td>
<td>101</td>
<td>12%</td>
</tr>
<tr>
<td>Total Client</td>
<td><strong>131</strong></td>
<td><strong>117</strong></td>
<td><strong>147</strong></td>
<td><strong>134</strong></td>
<td><strong>130</strong></td>
<td><strong>89</strong></td>
<td><strong>36</strong></td>
<td><strong>30</strong></td>
<td><strong>11</strong></td>
<td><strong>825</strong></td>
<td><strong>100%</strong></td>
</tr>
</tbody>
</table>
The Case History of Herat – Next steps and needs

- Training for mastectomy and breast surgery for local doctors
- Set-up of protocols for mastectomy, chemotherapy and radiotherapy for breast malignant tumor
- Establishment of a proper follow-up system for patients after treatment
- Conducting regular system of assessment (questionnaire) to find cases of breast cancer outside the region
- Awareness raising campaigns on breast cancer prevention through different activities such as:
  - free phone line for answering to questions regarding breast cancer issues
  - local radio/TV spots about breast cancer Center with the invitation to get an appointment
Fondazione Umberto Veronesi
Via Solferino 19, 20121 Milano
+39 02 76018187

Annamaria Parola
annamaria.parola@fondazioneveronesi.it
Head of Public Relations and International Projects

fondazioneveronesi.it